GSB Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GSB Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$893	Hold	7	–	–	﹤0.01%	235
2025 Q4	$854	Hold	7	–	–	﹤0.01%	231
2025 Q3	$701	Buy	7 +3	+75%	+$270	﹤0.01%	239
2025 Q2	$357	Hold	4	–	–	﹤0.01%	239
2025 Q1	$350	Buy	+4	New	+$358	﹤0.01%	227
2024 Q4	–	Sell	-4	Closed	-$428	–	244
2024 Q3	$428	Buy	+4	New	+$393	﹤0.01%	232
2023 Q2	–	Sell	-24	Closed	-$1.97K	–	235
2023 Q1	$1.97K	Buy	+24	New	+$1.99K	﹤0.01%	214
2022 Q3	–	Sell	-3,023	Closed	-$225K	–	205
2022 Q2	$225K	Sell	3,023 -5,222	-63%	-$392K	0.08%	196
2022 Q1	$741K	Sell	8,245 -18,397	-69%	-$1.7M	0.22%	138
2021 Q4	$2.98M	Buy	26,642 +1,249	+5%	+$151K	0.86%	30
2021 Q3	$3.19M	Buy	25,393 +860	+4%	+$111K	1.64%	16
2021 Q2	$3.32M	Buy	24,533 +1,418	+6%	+$186K	1.03%	20
2021 Q1	$3.14M	Buy	+23,115	New	+$3.46M	1.04%	21

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GSB Wealth Management's XBI Position: Q1 2026 in Review

GSB Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 7 shares worth $893. The position accounts for ﹤0.01% of the portfolio, ranked #235.

GSB Wealth Management first reported a position in XBI in Q1 2021 and has held it in 13 quarters since. The position peaked at $3.32M in Q2 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

GSB Wealth Management held 7 shares of State Street SPDR S&P Biotech ETF worth $893 as of Q1 2026.
GSB Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of GSB Wealth Management's portfolio in Q1 2026, its #235 holding.
GSB Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 13 quarters since.
GSB Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $3.32M in Q2 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on GSB Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.